Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer

References

• Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, et al. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist. 2013;18(12):1298-1306. doi:10.1634/theoncologist.2013-0321
   Google Scholar
• Partridge AH, Ruddy KJ, Kennedy J, Winer EP. Model program to improve care for a unique cancer population: young women with breast cancer. J Oncol Pract. 2012;8(5):e105–10. doi:10.1200/JOP.2011.000501
   Google Scholar
• Villarreal-Garza C, Platas A, Miaja M, et al. Young women with breast cancer in Mexico: results of the pilot phase of the Joven & Fuerte prospective cohort. JCO Glob Oncol. 2020;6:395–406. doi:10.1200/JGO.19.00264
   Google Scholar
• Zimmer AS, Zhu K, Steeg PS, et al. Analysis of breast cancer in young women in the Department of Defense (DOD) database. Breast Cancer Res Treat. 2018;168(2):501–511. doi:10.1007/s10549-017-4615-8
   Web of Science ®Google Scholar
• Seneviratne S, Lawrenson R, Harvey V, et al. Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology. BMC Cancer. 2016;16:129. doi:10.1186/s12885-016-2177-5
   PubMed Web of Science ®Google Scholar
• Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (< 35 years) are different. Br J Cancer. 1996;74(11):1796–1800. doi:10.1038/bjc.1996.632
   Web of Science ®Google Scholar
• Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324–3330. doi:10.1200/JCO.2007.14.2471
   PubMed Web of Science ®Google Scholar
• Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001;92(10):2523–2528. doi:10.1002/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Villarreal-Garza C, Mohar A, Bargallo-Rocha JE, et al. Molecular subtypes and prognosis in young Mexican women with breast cancer. Clin Breast Cancer. 2017;17(3):e95–e102. doi:10.1016/j.clbc.2016.11.007
   Google Scholar
• Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea–a report from the Korean Breast Cancer Society. J Clin Oncol. 2007;25(17):2360–2368. doi:10.1200/JCO.2006.10.3754
   Web of Science ®Google Scholar
• Azim HA, Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18(5):1341–1351. doi:10.1158/1078-0432.CCR-11-2599
   PubMed Web of Science ®Google Scholar
• Villarreal-Garza C, Reynoso-Noveron N, Arce-Salinas C, et al. Abstract P6-08-55: high triple-negative breast cancer prevalence and poor outcome of hormone receptor positive breast cancer among young Mexican women. Cancer Res. 2015;75(9Supplement):P6-08-55-P6-08-55. doi:10.1158/1538-7445.SABCS14-P6-08-55
   Web of Science ®Google Scholar
• Tang L-C, Jin X, Yang H-Y, et al. Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China. BMC Cancer. 2015;15:201. doi:10.1186/s12885-015-1207-z
   Web of Science ®Google Scholar
• Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–4128. doi:10.1200/JCO.2009.25.9655
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly RM, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5):832–839. doi:10.1002/cncr.22485
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–2269. doi:10.1200/JCO.2013.54.2258
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–1467. doi:10.1016/S0140-6736(97)11423-4
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99(11):1763–1768. doi:10.1038/sj.bjc.6604758
   PubMed Web of Science ®Google Scholar
• Wuensch P, Hahne A, Haidinger R, et al. Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor? J Cancer Res Clin Oncol. 2015;141(1):55–60. doi:10.1007/s00432-014-1779-z
   PubMed Web of Science ®Google Scholar
• Cluze C, Rey D, Huiart L, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol. 2012;23(4):882–890. doi:10.1093/annonc/mdr330
   PubMed Web of Science ®Google Scholar
• Huiart L, Bouhnik AD, Rey D, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer. 2012;48(13):1939–1946. doi:10.1016/j.ejca.2012.03.004
   Web of Science ®Google Scholar
• Pagani O, Gelber S, Colleoni M, Price KN, Simoncini E. Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13–93 and 14–93. Breast Cancer Res Treat. 2013;142(2):455–459. doi:10.1007/s10549-013-2757-x
   PubMed Web of Science ®Google Scholar
• Brito C, Portela MC, de Vasconcellos MTL. Adherence to hormone therapy among women with breast cancer. BMC Cancer. 2014;14:397. doi:10.1186/1471-2407-14-397
   PubMed Web of Science ®Google Scholar
• Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization: Geneva, Switzerland; 2003.
   Google Scholar
• Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–478. doi:10.1007/s10549-012-2114-5
   PubMed Web of Science ®Google Scholar
• Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27(21):3445–3451. doi:10.1200/JCO.2008.19.2419
   PubMed Web of Science ®Google Scholar
• Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention: table 1. Cancer Prev Res. 2011;4(9):1360–1365. doi:10.1158/1940-6207.CAPR-11-0380
   PubMed Web of Science ®Google Scholar
• Stanton AL, Petrie KJ, Partridge AH. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat. 2014;145(2):525–534. doi:10.1007/s10549-014-2961-3
   Web of Science ®Google Scholar
• Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215–220. doi:10.1007/s10549-006-9193-0
   PubMed Web of Science ®Google Scholar
• Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–118. doi:10.1056/NEJMoa1404037
   PubMed Web of Science ®Google Scholar
• Swedish Breast Cancer Cooperative Group. Swedish breast cancer cooperative. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst. 1996;88(21):1543–1549. doi:10.1093/jnci/88.21.1543
   PubMedGoogle Scholar
• Geiger AM, Thwin SS, Lash TL, et al. Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer. 2007;109(5):966–974. doi:10.1002/cncr.22472
   Web of Science ®Google Scholar
• Ulcickas Yood M, Owusu C, Buist DSM, et al. Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg. 2008;206(1):66–75. doi:10.1016/j.jamcollsurg.2007.07.015
   Web of Science ®Google Scholar
• Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst. 2001;4181(30):56–61. doi:10.1093/oxfordjournals.jncimonographs.a003462
   Google Scholar
• Wassermann J, Gelber SI, Rosenberg SM, et al. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. Cancer. 2019;125(18):3266–3274. doi:10.1002/cncr.32192
   Web of Science ®Google Scholar
• Oguntola AS, Adeoti ML, Akanbi OO. Non-adherence to the use of tamoxifen in the first year by the breast cancer patients in an African Population. East Cent Afr J Surg. 2011;16(1):52–56, tab.
   Google Scholar
• Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59:97–102. doi:10.1016/j.pec.2004.10.005
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. doi:10.1056/NEJMra050100
   PubMed Web of Science ®Google Scholar
• Pistilli B, Paci A, Ferreira AR, et al. Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol. 2020;38(24):2762–2772. doi:10.1200/JCO.19.01758
   PubMed Web of Science ®Google Scholar
• Costa JDM, Torres TS, Coelho LE, Luz PM. Adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean: systematic review and meta-analysis. J Int AIDS Soc. 2018;21(1):e25066. doi:10.1002/jia2.25066
   Web of Science ®Google Scholar
• Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep. 2014;11(3):291–307. doi:10.1007/s11904-014-0220-1
   PubMed Web of Science ®Google Scholar
• Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602–606. doi:10.1200/JCO.2003.07.071
   PubMed Web of Science ®Google Scholar
• Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652–661. doi:10.1093/jnci/94.9.652
   PubMed Web of Science ®Google Scholar
• Brett J, Boulton M, Fenlon D, et al. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. Patient Prefer Adherence. 2018;12:291–300. doi:10.2147/PPA.S145784
   PubMed Web of Science ®Google Scholar
• Wengström Y, Aapro M, Leto Di Priolo S, Cannon H, Georgiou V. Patients’ knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast. 2007;16(5):462–468. doi:10.1016/j.breast.2007.02.007
   PubMed Web of Science ®Google Scholar
• Clancy C, Lynch J, OConnor P, Dowling M. Breast cancer patients’ experiences of adherence and persistence to oral endocrine therapy: a qualitative evidence synthesis. Eur J Oncol Nurs. 2020;44:101706. doi:10.1016/j.ejon.2019.101706
   PubMed Web of Science ®Google Scholar
• Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–567. doi:10.1016/S0022-3999(99)00057-4
   PubMed Web of Science ®Google Scholar
• Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor–positive breast cancer. J Clin Oncol. 2004;22(16):3309–3315. doi:10.1200/JCO.2004.11.064
   PubMed Web of Science ®Google Scholar
• Bright EE, Petrie KJ, Partridge AH, Stanton AL. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Breast Cancer Res Treat. 2016;158(2):243–251. doi:10.1007/s10549-016-3871-3
   PubMed Web of Science ®Google Scholar
• Owusu C, Buist DSM, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549–555. doi:10.1200/JCO.2006.10.1022
   PubMed Web of Science ®Google Scholar
• Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007;45(5):431–439. doi:10.1097/01.mlr.0000257193.10760.7f
   PubMed Web of Science ®Google Scholar
• Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use side effects, and discontinuation in older women. J Clin Oncol. 2001;19(2):322–328. doi:10.1200/JCO.2001.19.2.322
   PubMed Web of Science ®Google Scholar
• Wouters H, Stiggelbout AM, Bouvy ML, et al. Endocrine therapy for breast cancer: assessing an array of women’s treatment experiences and perceptions, their perceived self-efficacy and nonadherence. Clin Breast Cancer. 2014;14(6):460–467.e2. doi:10.1016/j.clbc.2014.04.005
   Web of Science ®Google Scholar
• Robinson B, Dijkstra B, Davey V, Tomlinson S, Frampton C. Adherence to adjuvant endocrine therapy in Christchurch women with early breast cancer. Clin Oncol. 2018;30(1):e9–e15. doi:10.1016/j.clon.2017.10.015
   Web of Science ®Google Scholar
• Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009;20(January):431–436. doi:10.1093/annonc/mdn646
   Web of Science ®Google Scholar
• Moon Z, Moss-Morris R, Hunter MS, Hughes LD. Understanding tamoxifen adherence in women with breast cancer: a qualitative study. Br J Health Psychol. 2017;22(4):978–997. doi:10.1111/bjhp.12266
   PubMed Web of Science ®Google Scholar
• He W, Smedby KE, Fang F, et al. Treatment restarting after discontinuation of adjuvant hormone therapy in breast cancer patients. J Natl Cancer Inst. 2017;109(10). doi:10.1093/jnci/djx041
   Google Scholar
• Benedict C, Thom B, Teplinsky E, Carleton J, Kelvin JF. Family-building after breast cancer: considering the effect on adherence to adjuvant endocrine therapy. Clin Breast Cancer. 2017;17(3):165–170. doi:10.1016/j.clbc.2016.12.002
   Web of Science ®Google Scholar
• Rosenberg SM, Partridge AH. New insights into nonadherence with adjuvant endocrine therapy among young women with breast cancer. J Natl Cancer Inst. 2015;107(10):djv245. doi:10.1093/jnci/djv245
   Google Scholar
• Llarena NC, Estevez SL, Tucker SL, Jeruss JS. Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. 2015;107(10):djv202. doi:10.1093/jnci/djv202
   Google Scholar
• Villarreal-Garza C, Martinez-Cannon BA, Platas A, et al. Fertility concerns among breast cancer patients in Mexico. Breast. 2017;33:71–75. doi:10.1016/j.breast.2017.02.010
   PubMed Web of Science ®Google Scholar
• Villarreal-Garza C, Platas A, Bargalló-Rocha JE, et al. Information needs and internet use of breast cancer patients in Mexico. San Antonio Breast Cancer Symposium.
   Google Scholar